RFA for Superficial Lipomas
NCT06903208
Recruiting
Lipomas are non-cancerous growths of fatty tissue that develop under the skin in approximately 1 in 1000 people, though this number may be higher. While rarely symptomatic, they often cause emotional distress due to the unappealing appearance of the mass. Treatment of unsightly lipomas is excision with local anesthetic in the office or with sedation in the operating room. The recovery period is short and the procedure is low risk; however, the result of the operation is a visible scar over the s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Lipoma
Register for Updates
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
NCT01746836
Recruiting
This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells by blocking a protein needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Register for Updates
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +101 locations
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
A Framework for Linking Sequential Pattern Rules in DLD: Perception in Toddlers
NCT04531514
Recruiting
This broad aim of this clinical study is to assess the hypothesis that morphological and phonological deficits are linked by a broader deficit in sequential pattern learning. This hypothesis applies to learning in general, but is especially critical as an avenue for developing earlier assessments and more powerful interventions for children with developmental language disorder (DLD; AKA specific language impairment). Other populations, such as at-risk toddlers, may also benefit from this new app... Read More
Gender:
ALL
Ages:
Between 19 months and 36 months
Trial Updated:
03/24/2025
Locations: University of Arizona, Tucson, Arizona +1 locations
Conditions: Developmental Language Disorder, Speech Sound Disorder, Specific Language Impairment
Register for Updates
Virtual Neuro-Navigation System for Personalized Community Based TMS
NCT04956081
Recruiting
Phase I study of a virtual neuro-navigation package with built-in support for identifying specific "surface-based" targets to optimze TMS treatment.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/24/2025
Locations: Columbia Docs, New York, New York
Conditions: Treatment Resistant Depression
Register for Updates
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
NCT05337631
Recruiting
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and al... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/24/2025
Locations: Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland +17 locations
Conditions: HNSCC, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
Register for Updates
Evaluation of GeoHAI Implementation
NCT05612672
Recruiting
Geographic Information Systems (GIS) and spatial analysis have become important tools in public health informatics but have rarely been applied to the hospital setting. In this study we apply these tools to address the challenge of Hospital Acquired Infections (HAIs) by building, implementing, and evaluating a new computer application which incorporates mapping and geographic data to assist hospital epidemiologists in identifying HAI clusters and assessing transmission risk. We expect that incor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Clostridioides Difficile Infection, Healthcare Associated Infection
Register for Updates
MDMA-Assisted Therapy for Veterans with Moderate to Severe Post Traumatic Stress Disorder
NCT05790239
Recruiting
This randomized, double-blind, single-site phase II 2-arm study will investigate the safety and preliminary efficacy of MDMA-assisted therapy compared with low dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in participants aged 18 years and older with PTSD of at least moderate severity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: VA Greater Los Angeles Healthcare System, Westwood campus, Los Angeles, California +1 locations
Conditions: Post Traumatic Stress Disorder
Register for Updates
NG101 AAV Gene Therapy in Subjects with Wet Age-Related Macular Degeneration
NCT05984927
Recruiting
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
03/24/2025
Locations: Cincinnati Eye Institute, Cincinnati, Ohio +3 locations
Conditions: Age-Related Macular Degeneration
Register for Updates
Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors
NCT06128551
Recruiting
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.
Gender:
ALL
Ages:
Between 18 years and 125 years
Trial Updated:
03/24/2025
Locations: City of Hope, Duarte, California +53 locations
Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Revumenib in Combination With 7+3 + Midostaurin in AML
NCT06313437
Recruiting
This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). The names of the study drugs involved in this study are: * Re... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
Register for Updates
Laser In Situ Fenestration Study
NCT06411990
Recruiting
The goal of this clinical trial is to learn about a new device, named the LIFE device, to treat people with aneurysms (swellings) in the aorta (large, main blood vessel that delivers blood from the heart to the body). The main questions this trial aims to answer are: * If the LIFE device works to treat aortic aneurysms * What medical problems participants have when the LIFE device is used Participants will undergo treatment with the LIFE device and thereafter at 30 days, 6 months, 1 year, 2 yea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Missouri - Columbia, Columbia, Missouri
Conditions: Aortic Aneurysm, Endovascular Aneurysm Repair
Register for Updates